Eliana Merle
Stock Analyst at UBS
(3.80)
# 715
Out of 5,090 analysts
96
Total ratings
50.7%
Success rate
9.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Buy | $70 → $40 | $25.49 | +56.96% | 8 | Oct 23, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $72 → $82 | $74.74 | +9.71% | 4 | Sep 12, 2025 | |
| GOSS Gossamer Bio | Upgrades: Buy | $1.25 → $9 | $3.38 | +166.67% | 3 | Sep 10, 2025 | |
| ALT Altimmune | Maintains: Buy | $26 → $24 | $5.31 | +351.98% | 2 | Aug 13, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Neutral | $8 → $9 | $34.40 | -73.84% | 4 | Aug 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $458 → $523 | $591.06 | -11.51% | 5 | Aug 12, 2025 | |
| ANAB AnaptysBio | Maintains: Neutral | $18 → $20 | $43.05 | -53.54% | 5 | Aug 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $306 → $307 | $208.09 | +47.53% | 2 | Aug 8, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $113 → $114 | $53.82 | +111.84% | 3 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $403 → $550 | $464.56 | +18.39% | 3 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $22.81 | -47.39% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $2.58 | +210.08% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $5.5 | $5.12 | +7.42% | 3 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $12.62 | +66.47% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $66.56 | +5.17% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $22.05 | +99.59% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $109 | $54.59 | +99.69% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $1.41 | +56.03% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $78.51 | -9.56% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $21.97 | +27.46% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.37 | +88.38% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $3 | $4.13 | -27.36% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $95.99 | +36.47% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $24.51 | -79.60% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $27.21 | -33.85% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $23.09 | +81.90% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $17.27 | +27.39% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $13.10 | +258.78% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.93 | +61.18% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $31.82 | +321.18% | 3 | Aug 19, 2020 |
Moderna
Oct 23, 2025
Maintains: Buy
Price Target: $70 → $40
Current: $25.49
Upside: +56.96%
BridgeBio Pharma
Sep 12, 2025
Maintains: Buy
Price Target: $72 → $82
Current: $74.74
Upside: +9.71%
Gossamer Bio
Sep 10, 2025
Upgrades: Buy
Price Target: $1.25 → $9
Current: $3.38
Upside: +166.67%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $5.31
Upside: +351.98%
RAPT Therapeutics
Aug 12, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $34.40
Upside: -73.84%
Madrigal Pharmaceuticals
Aug 12, 2025
Maintains: Buy
Price Target: $458 → $523
Current: $591.06
Upside: -11.51%
AnaptysBio
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $43.05
Upside: -53.54%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $306 → $307
Current: $208.09
Upside: +47.53%
BioMarin Pharmaceutical
Aug 5, 2025
Maintains: Buy
Price Target: $113 → $114
Current: $53.82
Upside: +111.84%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $403 → $550
Current: $464.56
Upside: +18.39%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $22.81
Upside: -47.39%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $2.58
Upside: +210.08%
Jun 26, 2025
Downgrades: Neutral
Price Target: $12 → $5.5
Current: $5.12
Upside: +7.42%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $12.62
Upside: +66.47%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $66.56
Upside: +5.17%
Apr 29, 2025
Initiates: Overweight
Price Target: $44
Current: $22.05
Upside: +99.59%
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $54.59
Upside: +99.69%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.41
Upside: +56.03%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $78.51
Upside: -9.56%
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $21.97
Upside: +27.46%
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $6.37
Upside: +88.38%
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $4.13
Upside: -27.36%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $95.99
Upside: +36.47%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $24.51
Upside: -79.60%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $27.21
Upside: -33.85%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $23.09
Upside: +81.90%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $17.27
Upside: +27.39%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $13.10
Upside: +258.78%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.93
Upside: +61.18%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $31.82
Upside: +321.18%